Real Madrid are tracking AZ Alkmaar midfielder Kees Smit ahead of a summer transfer move, according to journalist Fabrizio Romano. Newcastle United previously failed with a swoop in the winter ...

February 19, 2026 (Sioux Falls, SD) – TAK Broadband, LLC ("TAK") is providing notice of a data security incident that may involve information relating to certain individuals. On August 11, 2025, TAK ...

Bij een brand in een appartementencomplex in het Spaanse Manlleu, 60 kilometer ten noorden van Barcelona, zijn maandagavond vijf tieners omgekomen. De tieners zaten in een krappe berging op de ...

Liverpool have overtaken Bayern Munich in the race for supreme Dutch talent Kees Smit, though Arsenal are among two other heavyweight clubs also pursuing him, according to a report. Smit is a ...

In de nacht van maandag op dinsdag is aan de Dorpsstraat in Lunteren een houten berging volledig verwoest door een uitslaande brand. Ook een geparkeerde auto raakte zwaar beschadigd. De politie is een ...

Milan Smit scored nine goals in 25 games for Go Ahead Eagles this season before his move to Stoke City in January Striker Milan Smit says he joined Stoke City to play in the Premier League and to ...

Striker Milan Smit says he joined Stoke City to play in the Premier League and to become a more "complete" player. The Dutch forward, 22, moved to the Potters in the January transfer window on an ...

Liverpool are in talks to sign Kees Smit from AZ Alkmaar and bring him to Anfield in the January transfer window, according to a source, with Arne Slot’s side also pressing ahead for two defenders ...

Spelersvakbond VVCS heeft geen goed woord over voor AZ en NEC. De clubs willen de Portugese topmakelaar Jorge Mendes inschakelen om Kees Smit (AZ) en Kodai Sano (NEC) voor topbedragen te verkopen, ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best healthcare stocks to buy for 2026. Takeda Pharmaceutical Company Limited (NYSE:TAK) reported Q3 FY2025 results on January 29, 2026, ...

Earnings call Takeda’s Q3 FY2025 revenue declined 3.3% YoY (−2.8% CER), driven by Vyvanse LOE, but core operating profit held steady at −3.4% YoY. Growth and launch products rose 6.7% CER, offsetting ...